enGene Therapeutics (ENGN) Restructuring Costs (2025 - 2026)
enGene Therapeutics (ENGN) posted quarterly Restructuring Costs of $4.1 million for Q2 2026, up 64.1% year-over-year from $2.5 million in Q2 2025, and up 8.0% quarter-over-quarter from $3.8 million in Q1 2026.
enGene Therapeutics (ENGN) Restructuring Costs (2025 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Restructuring Costs for 2 consecutive years, with $4.1 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Restructuring Costs rose 64.1% year-over-year to $4.1 million; the TTM figure through Apr 2026 stood at $13.4 million (changed N/A YoY), while the FY2025 annual figure was $11.5 million, down 4.02% from the prior year.
- Restructuring Costs rose to $4.1 million in Q2 2026 per ENGN's latest filing, from $3.8 million in the prior quarter.
- Across five years, Restructuring Costs topped out at $4.1 million in Q2 2026 and bottomed at $2.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | enGene Therapeutics | 124.11 Mn | 124.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 4.09 Mn |
| Jan 31, 2026 | 3.79 Mn |
| Apr 30, 2025 | 2.49 Mn |
| Jan 31, 2025 | 3.03 Mn |